These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8530574)

  • 1. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
    Heiner JS; Greendale GA; Kawakami AK; Lapolt PS; Fisher M; Young D; Judd HL
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3412-8. PubMed ID: 8530574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
    Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.
    Azziz R; Ochoa TM; Bradley EL; Potter HD; Boots LR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3406-11. PubMed ID: 8530573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
    Elkind-Hirsch KE; Anania C; Mack M; Malinak R
    Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
    Castelo-Branco C; Martínez de Osaba MJ; Pons F; Fortuny A
    Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women.
    Ruutiainen K
    Int J Gynaecol Obstet; 1986 Oct; 24(5):361-8. PubMed ID: 2880770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.
    Tiitinen A; Simberg N; Stenman UH; Ylikorkala O
    J Clin Endocrinol Metab; 1994 Aug; 79(2):447-51. PubMed ID: 8045961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
    Carmina E; Janni A; Lobo RA
    J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome.
    Raj SG; Raj MH; Talbert LM; Sloan CS; Hicks B
    Obstet Gynecol; 1982 Jul; 60(1):15-9. PubMed ID: 7201126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
    Surrey ES; Judd HL
    J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism.
    Falsetti L; Pasinetti E; Ceruti D
    Acta Eur Fertil; 1994; 25(5):303-6. PubMed ID: 7660719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
    Oner G; Muderris II
    Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
    Dodin S; Faure N; Cédrin I; Méchain C; Turcot-Lemay L; Guy J; Lemay A
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):575-82. PubMed ID: 8548942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.
    Rittmaster RS
    J Clin Endocrinol Metab; 1988 Oct; 67(4):651-5. PubMed ID: 3138274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
    Grinspoon S; Thomas L; Miller K; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2883-91. PubMed ID: 12050268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills.
    Escobar-Morreale HF; Avila S; Sancho J
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2488-92. PubMed ID: 10902798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
    Boyd RA; Zegarac EA; Posvar EL; Flack MR
    Contraception; 2001 Feb; 63(2):71-6. PubMed ID: 11292470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.